Targeting the P2X7 receptor reduces harmful human brain inflammation
Researchers found that blocking the P2X7 receptor significantly reduced brain inflammation, offering a potential path to repurpose existing drugs for neurological conditions.
FTMQ Health, written by our newsroom0 views

Science Daily Exercise reported that researchers have identified a new strategy to reduce harmful brain inflammation by targeting a receptor known as P2X7. Blocking this receptor significantly reduced inflammation in human brain tissue, according to study findings published in the journal Brain. Professor Nicholas Barnes at the University of Birmingham led the research team. [1]
The discovery shows that scientists may be able to repurpose existing drugs that already block the P2X7 receptor. Science Daily Exercise reported that this therapeutic approach could target conditions such as traumatic brain injury, Alzheimer's disease, Parkinson's disease, depression, and schizophrenia. [1]
Alzheimer's disease is a neurodegenerative disorder that represents the most common cause of dementia, accounting for roughly 60% to 70% of cases. The condition leads to progressive memory loss, behavioral changes, and the loss of bodily functions. [3]
Medical treatments for related chronic neurological disorders also include therapies such as deep brain stimulation. That surgical treatment uses an implanted pulse generator in the chest to send controlled electrical impulses to dysfunctional circuits in the brain. [4]
In short
- Blocking the P2X7 receptor significantly reduced inflammation in human brain tissue.
- Professor Nicholas Barnes led the study published in the journal Brain.
- Alzheimer's disease accounts for approximately 60% to 70% of dementia cases.
- Targeting the P2X7 receptor could help repurpose existing drugs for Alzheimer's disease and Parkinson's disease.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Drug target could block brain inflammation linked to Alzheimer’s and Parkinson’sScience Daily Exercise, 46d ago (the report this story comes from)
- [2]Biomedicine | China steps up Alzheimer’s, Parkinson’s drug push, looks to TCMSouth China Morning Post, 47d ago
Background
- [3]Alzheimer's disease on Wikipedia
- [4]Deep brain stimulation on Wikipedia
Our newsroom writes these reports with the help of software, from the 4 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- RIPK1 Inhibitors Match Placebo Safety in Human Clinical TrialsMedical Science, 6d ago
- UK clinical trial tests repurposed diabetes and ADHD drugs for Alzheimer diseaseTop Stories, 31d ago
- Study links four industrial solvents to higher odds of Parkinson's diseaseTop Stories, 3d ago
- Review links air pollution and socioeconomic status to Parkinson's disease riskPublic Health, 6d ago
- AI chatbots direct users to private clinic stem cell claimsTop Stories, 16d ago
More in Fitness
- Blood antibody patterns predict inflammatory bowel disease a decade early28d ago
- Ear nerve stimulation shows promise for severe high blood pressure28d ago
- Red meat sugar linked to higher type 2 diabetes risk34d ago
- Kenyan and Canadian Runners Secure Wins at 2026 Toronto Waterfront Races34d ago
- Physical activity improves mood and quality of life during menopause35d ago
- Late night eating linked to higher risk of liver disease37d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.